NeuroOne Medical Technologies Announces Inducement Grant for New Employee Under Nasdaq Rules

NeuroOne Medical Technologies Corporation announced that its independent directors approved an equity award under the company's 2021 Inducement Plan as a material inducement for an individual entering employment with the company. The award was made in accordance with Nasdaq Listing Rule 5635(c)(4), which mandates public disclosure of equity awards not made under stockholder-approved plans. This regulatory requirement ensures transparency for investors regarding compensation practices that fall outside typical equity plans.

The new employee, who was not previously associated with NeuroOne as an employee or director, received an option to purchase 10,000 shares of common stock at an exercise price of $0.802 per share. This price matches the closing price of NeuroOne's common stock on April 1, 2026, the grant date. The option has a ten-year term and vests over four years, with 25% vesting on April 1, 2027, and the remaining 75% vesting in twelve equal quarterly installments thereafter. Vesting is contingent on continued employment and subject to acceleration or forfeiture provisions outlined in the option agreement.

This inducement grant reflects NeuroOne's ongoing efforts to attract talent to support its medical technology initiatives. The company focuses on improving surgical care for neurological disorders through its FDA-cleared product families, including Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for brain applications, and OneRF Trigeminal Nerve Ablation System. These technologies aim to reduce hospitalizations, lower costs, and enhance patient outcomes by combining diagnostic and therapeutic functions. NeuroOne is also engaged in research and development for drug delivery and spinal cord stimulation programs, with more information available at https://nmtc1.com.

The announcement underscores the importance of regulatory compliance in corporate governance, particularly for publicly traded companies like NeuroOne listed on Nasdaq. By following Nasdaq Listing Rule 5635(c)(4), the company maintains transparency with shareholders and the broader market regarding executive compensation and hiring incentives. Such disclosures help investors assess how companies allocate resources to recruit key personnel who can drive innovation and growth in competitive sectors like medical technology.

Inducement grants are commonly used to attract high-caliber employees who bring specialized skills or experience to a company. In NeuroOne's case, this practice aligns with its mission to transform the surgical diagnosis and treatment of neurological disorders. The structured vesting schedule incentivizes long-term commitment from the new hire, potentially fostering stability and continuity in the company's operations. As NeuroOne continues to develop and market its electrode technology platform, strategic hiring supported by such equity awards may play a crucial role in advancing its clinical and commercial objectives.